Jumpcan Pharma updates progress on share repurchase plan
Hubei Jumpcan Pharmaceutical (SSE:600566) announced the progress of its share repurchase plan via centralized bidding transactions. As of June 30, 2025, the company has repurchased 914,200 shares, representing 0.10% of the total share capital. The highest purchase price was CNY 29.00 per share, and the lowest was CNY 26.17 per share. The total expenditure amounted to CNY 25,005,955 (excluding transaction costs). This repurchase is intended for employee stock ownership plans or equity incentives. The company's board approved the repurchase plan initially on July 22, 2024, with a total repurchase amount between CNY 25 million and CNY 50 million. The company will continue to implement the repurchase plan based on market conditions and in accordance with relevant regulations.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Hubei Jumpcan Pharmaceutical publishes news
Free account required • Unsubscribe anytime